AT7687vsTirzepatide

AT7687 is a long-acting GIP receptor antagonist designed to reduce fat storage rather than suppress appetite — a fundamentally different mechanism from every other obesity drug currently on the market or in late-stage development. The rationale is grounded in human genetics: loss-of-function variants in the GIP receptor are associated with lower body mass index and reduced cardiometabolic risk, suggesting that pharmacologically blocking GIP signalling should reproduce these protective effects.

GIP (glucose-dependent insulinotropic polypeptide) normally functions as a fat-storage signal — released from intestinal K-cells in response to food intake, it instructs adipose tissue to take up and store circulating fatty acids. By blocking the GIP receptor specifically on adipocytes, AT7687 prevents this fat-storage signal from being transmitted, leading to reduced lipid uptake into fat cells and a metabolic shift favouring fat oxidation in muscle and liver. Because the mechanism does not depend on suppressing hunger or slowing gastric emptying, the gastrointestinal side effects that limit GLP-1 drug tolerability are largely absent.

This mechanism is the conceptual mirror of MariTide (which combines GLP-1 agonism with GIP antagonism in a single molecule) — AT7687 isolates the GIP-antagonist component to test whether it can produce meaningful weight loss alone or in future combination with GLP-1 agonists. Antag Therapeutics' first-in-human Phase 1 results in 2026 showed acceptable tolerability with mild GI symptoms, plus reductions in LDL cholesterol and resting heart rate — early signals consistent with the predicted cardiometabolic benefit profile. Phase 2 trials are expected to define the magnitude of weight loss achievable in obese patients.

Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.

The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.

At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.